IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v8y2024i5d10.1007_s41669-024-00491-w.html
   My bibliography  Save this article

Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story

Author

Listed:
  • She Hui Tan

    (Ministry of Health)

  • Louise Gek Huang Goh

    (Ministry of Health)

  • Benjamin Shao Kiat Ong

    (Ministry of Health)

  • Darren Sze Guan Ng

    (Ministry of Health)

  • Liang Lin

    (Ministry of Health)

  • Raymond Chee Hui Ng

    (National Cancer Centre Singapore)

  • Bernard Yu-Hor Thong

    (Tan Tock Seng Hospital Singapore)

  • Kwong Ng

    (Ministry of Health)

Abstract

Background Healthcare sustainability is a global challenge. Various value-driven healthcare strategies have been implemented by Singapore’s national health technology assessment (HTA) agency, the Agency for Care Effectiveness (ACE). Considering the high and growing expenditure on biologics, strategies have been implemented to drive the use of biosimilars. As Singapore has reached the 5-year mark since the subsidy listing of the first monoclonal antibody biosimilar infliximab, this review aimed to evaluate the impact of these strategies on the changes in adoption rates, utilisation, spending and cost savings for biosimilars in the public healthcare sector. Methods A retrospective cross-sectional study was conducted using aggregated drug utilisation data from all public healthcare institutions. Five monoclonal antibodies with biosimilars, namely infliximab, adalimumab, trastuzumab, rituximab and bevacizumab, were included in this study. The outcomes evaluated were the monthly trends for utilisation volume, proportion attributed to biosimilar use, and drug spending up to December 2022. The simulated cost savings associated with biosimilar adoption were also reported. Results After subsidy implementation, an upward trend in biosimilar use and proportion attributed to biosimilar adoption was observed, while spending reduced substantially. The adoption rate of most biosimilars reached more than 95% within 1 year of listing. Drugs with more than one approved biosimilar brand at the time of subsidy listing reported substantial price reductions of over 80%. Overall, spending for the five monoclonal antibodies have significantly reduced after biosimilar subsidy listing, with an estimated cumulative cost savings of $136 million over 5 years. Conclusion Value-driven healthcare strategies implemented in Singapore’s public healthcare institutions have contributed to high adoption rates of biosimilars and have improved affordable access through lower treatment costs. This in turn has led to significant cost savings to the healthcare system.

Suggested Citation

  • She Hui Tan & Louise Gek Huang Goh & Benjamin Shao Kiat Ong & Darren Sze Guan Ng & Liang Lin & Raymond Chee Hui Ng & Bernard Yu-Hor Thong & Kwong Ng, 2024. "Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story," PharmacoEconomics - Open, Springer, vol. 8(5), pages 679-688, September.
  • Handle: RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00491-w
    DOI: 10.1007/s41669-024-00491-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-024-00491-w
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-024-00491-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00491-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.